Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

December 31, 2026

Conditions

Kidney Transplant Infection

Interventions

DRUG

Belatacept

Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV

Trial Locations (1)

RECRUITING

University Rouen Hospital, Rouen

All Listed Sponsors

lead

University Hospital, Rouen

OTHER